Drug intelligence / Profile preview

EORA-204

Development stage: Unknown
Lead developer: Eolas Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

EORA-204 is a small molecule orexin-1 receptor antagonist being developed by Eolas Therapeutics for the treatment of cocaine-use disorder. It is part of the Eolas Orexin-1 Receptor Antagonist (EORA) program, which focuses on modulating neural reward pathways to address the brain circuitry of addiction. By selectively targeting the orexin-1 receptor (OX1R), EORA-204 aims to reduce drug craving and the motivation to consume cocaine without the sedative effects typically associated with orexin-2 receptor antagonism. The drug is designed to treat substance use disorders by directly addressing the underlying neurobiology of addiction. EORA-204 is currently in Phase 1 clinical development.

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)

Beyond the preview

Go deeper on EORA-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EORA-204.

Explore the full profile